DynamiCure is developing therapeutic antibody candidates that utilize immuno-normalization techniques to target cancer and autoimmune diseases. The company aims to provide effective treatment options that improve patient outcomes by addressing the underlying immune dysfunction associated with these conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers and autoimmune diseases are characterized by immune dysfunction, where the body's natural defenses are either suppressed or misdirected, leading to ineffective treatment outcomes. Current cancer treatments often fail to adequately address the immunosuppressive tumor microenvironment, limiting their efficacy across a broad range of tumor types.
Solution
DynamiCure is developing a pipeline of therapeutic antibody candidates that utilize immuno-normalization techniques to restore proper immune function in cancer and autoimmune conditions. Their lead program, DC-6001, targets the CD93 pathway to normalize malignant tumor vasculature, aiming to convert the tumor microenvironment from immunosuppressive to immunostimulatory. By binding to different epitopes of the CD93 receptor, DynamiCure's antibodies have the potential to enhance the effectiveness of combinatorial therapies across various tumor types. The DC-6001 program consists of two anti-CD93 monoclonal antibodies (DCBY02 and DCSZ11) that have demonstrated distinct in vitro and in vivo properties and anti-tumor activity in pre-clinical development.
Target Audience
The primary target audience includes patients with cancer and autoimmune diseases, as well as researchers and clinicians focused on developing and implementing novel immunotherapies.
Features
- DC-6001 targets the CD93 pathway, a novel mechanism for normalizing malignant tumor vasculature.
- DCBY02 and DCSZ11 are two anti-CD93 monoclonal antibodies with distinct properties and anti-tumor activity.
- Immuno-normalization approach aims to convert the tumor microenvironment from immunosuppressive to immunostimulatory.
- DCBY02 is currently being evaluated in a Phase 1 clinical trial (NCT05496595) for safety and anti-tumor activity in patients with advanced cancers.